GTx (GTXI)

3.14 +0.07  +2.28%  May 29, 5:20PM Go Pro
Watch this stock
View Full Chart GTXI Price Chart

Key Stats

Market Cap 197.19M
Revenue Growth -80.32%
Profit Margin -605.8%
Earnings Yield -22.61%
Dividend Yield 0.00%
Earnings Per Share TTM -0.71
PE Ratio
Price / Sales Ratio 27.11
52 Week High 6.864
52 Week Low 2.34
Beta 0.8331
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 29 GTx Announces Webcast of Corporate Presentation at Jefferies 2012 Global Healthcare C...
May 10 $GTXI filed latest Quarterly Report http://stks.co/3lmH by MarketBrief
May 10 GTX INC /DE/ Files SEC form 10-Q, Quarterly Report
May 09 New Star Analyst Rankings for GTx, Inc.
May 08 FDA withdraws hold on $GTXI prostate cancer drug http://stks.co/3jdv by abubnic
May 08 $GTXI Earnings losses of $11.1M trumped by news that they've moved past FDA concerns and can initiate clinical studies http://stks.co/3jdH by abubnic
May 08 Tuesday’s biggest gaining and declining stocks
May 08 GTx up on clearance for new Capesaris trials
May 08 What’s Moving These Hot Stocks: Fossil, GTX, SIRIUS XM, Chesapeake
May 08 $GTXI Downside Blowoff - 15 Minute Up Reversal - Green bar after 4 red bars by TradeIdeasQuant
May 08 $gtxi full reversal.. lod test and gap fill by kunal00

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Biotechnology

GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways. Its major product to date is Toremifene, and drugs in development include Ostarine and GTx-758. The company has undertaken partnerships with other biotechnology companies such as Merck in the development of drugs in the selective estrogen receptor modulator and selective androgen receptor modulator classes.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). GTx is down 45.10% over the last year vs S&P 500 Total Return up 1.18%, Protalix BioTherapeutics down 1.58%, and iBio down 60.65%.

  • GTXI Total Returns
  • ^SPXTR Total Returns
  • PLX Total Returns
  • IBIO Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Get Quote for

Pro Strategies Featuring GTXI

Did GTx make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

GTXI Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
GTXI 3.14 +0.07 +2.28% 192.80M
GTU 57.54 -0.86 -1.47%
GTSI 7.73 -0.01 -0.13% 74.69M
GTS 17.69 -0.10 -0.56% 505.77M
GTNA 1.33 +0.00 +0.00% 76.02M
GTN 1.45 +0.01 +0.69% 74.02M
GTLS 66.92 +2.78 +4.33% 1.901B
GTIM 2.25 -0.08 -3.43% 6.361M
GTI 11.14 +0.49 +4.60% 1.534B
GTE 5.21 +0.14 +2.76% 1.338B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close